Prof. Miaozhen Qiu 邱妙珍
Chief Physician, Professor
Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Medical treatment for gastrointestinal tumors, including gastric, colorectal, pancreatic, esophageal, gallbladder, and bile duct cancers.
Dr. Qiu is a Chief Physician, Professor, and Doctoral Supervisor at Sun Yat-sen University Cancer Center. Dr. Qiu completed a seven-year clinical medicine program at Sun Yat-sen University in 2008 and earned a PhD in 2015. From September 2014 to July 2016, Dr. Qiu was a postdoctoral fellow at Johns Hopkins University School of Medicine. Research focuses on chemotherapy, targeted therapy, immunotherapy for gastrointestinal tumors, and screening for hereditary gastric cancer.
Name order: in Chinese the family name comes first (Qiu Miaozhen). Papers usually list the name as Miaozhen Qiu or Qiu M.
Selected publications
149 papers on PubMed matched by name and affiliation; 35 as first or senior author since 2016. Most recent first- or senior-author papers:
- Nat Commun, 2026 (senior author): Vitamin B5 supports anti-PD1 response in HER2-positive gastric cancer and enhances interaction between naïve B cells and T cells. PubMed 42686743
- J Hematol Oncol, 2026 (senior author): Clinical benefit of PD-1 antibody plus chemotherapy in advanced HER2 negative gastric or gastro-oesophageal junction adenocarcinoma according to PD-L1 levels: Post-hoc analysis of RATIONALE-305 and pooled analysis of individual patient-level data. PubMed 42477829
- EClinicalMedicine, 2026 (first author): Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma, with or without peritoneal metastases: a post-hoc analysis on RATIONALE-305 study. PubMed 42205142
- Cancer, 2025 (first author): Tebotelimab plus niraparib in previously treated locally advanced or metastatic solid tumors: A phase 1b dose escalation and expansion study. PubMed 40445839
- Signal Transduct Target Ther, 2024 (first author): Addition of SHR-1701 to first-line capecitabine and oxaliplatin (XELOX) plus bevacizumab for unresectable metastatic colorectal cancer. PubMed 39676137
- Cancer Immunol Immunother, 2024 (senior author): Clinical outcomes and biomarker exploration of first-line PD-1 inhibitors plus chemotherapy in patients with low PD-L1-expressing of gastric or gastroesophageal junction adenocarcinoma. PubMed 38832979
- BMJ, 2024 (first author): Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial. PubMed 38806195
- Cancer Immunol Immunother, 2024 (senior author): The optimal threshold of PD-L1 combined positive score to predict the benefit of PD-1 antibody plus chemotherapy for patients with HER2-negative gastric adenocarcinoma: a meta-analysis. PubMed 38753055
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion